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Introduction
Osteoarthritis (OA) is the most common joint disorder in 
western populations. Its incidence increases with age, 
and thus this degenerative disease is a major problem in 
ageing populations. Th  e disease is characterized by a 
progressive degradation of articular cartilage leading to 
loss of joint mobility and function accompanied by 
chronic pain. On the biochemical level, OA is charac-
terized by uncontrolled production of matrix-degrading 
enzymes, including aggrecanases (a disintegrin and 
metallo  protease with trombospondine motifs (ADAMTSs)) 
and matrix metalloproteinases (MMPs), which result in 
the destruc  tion of cartilage matrix [1]. Other hallmarks 
of the disease are new bone formation at the joint 
margins (osteophytes), limited inﬂ  ammation (synovitis), 
and changes in subchondral bone structure (sclerosis). 
Th   e molecular mechanisms regulating pathogenesis and 
progression of OA, however, are only poorly 
understood, and no proven disease-modifying therapy 
is currently available. Remarkably, some characteristics 
of OA – that is, articular chondrocyte proliferation, the 
expression of hypertrophy markers (for example, 
MMP-13 and collagen X), remodeling of the cartilage 
matrix by proteases, vascularization and focal calciﬁ  -
cation of joint cartilage with calcium hydroxyapatite 
crystals – resemble chon  dro  cyte diﬀ  erentiation 
processes during skeletal develop  ment by endochondral 
ossiﬁ   cation (EO). Signal  ing molecules regulating 
chondrocyte activities in growth cartilage may thus also 
be involved in OA pathogenesis.
In the present review, current concepts for the control 
of late chondrocyte diﬀ   erentiation in EO will be 
discussed in the light of analogous events observed 
during the development of OA. Th  is knowledge is 
essential for the successful development of future 
therapeutic strategies.
Endochondral ossifi  cation
EO is important for development, growth, and repair of 
long bones. EO is initiated by the formation of cartilage 
templates of future bones, built by mesenchymal pro-
genitor cells, which condensate and diﬀ  erentiate  into 
chondrocytes. Within these bone anlagen, the diﬀ  er  en-
tiated cartilage cells then transit through a temporospatial 
cascade of late diﬀ   erentiation events that sequentially 
include proliferation and several steps of maturation, 
culminating in chondrocyte hypertrophy. After invasion 
of blood vessels from the subchondral bone, the majority 
of hypertrophic cells undergo apoptosis and the cartilage 
template is remodeled into trabecular bone [2]. 
Proliferation of chondrocytes, hypertrophic diﬀ  erentia-
tion of chondrocytes, remodeling and mineralization of 
the extracellular matrix (ECM), invasion of blood vessels 
and apoptotic death of chondrocytes correspondingly 
occur during OA.
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shape or cell arrangement [3,4] (Figure 1) and the expres-
sion of a speciﬁ  c protein repertoire. Collagen I, besides 
collagens III and V, is the major ﬁ  brillar component of 
undiﬀ  erentiated mesenchymal progenitor cells [5]. After 
diﬀ   erentiation into chondrocytes, the cells cease to 
produce collagens I, III, and V but start to express typical 
cartilage components, including collagens II, IX, and XI 
and the proteoglycan aggrecan [6]. During this diﬀ  eren-
tiation stage these so-called resting chondrocytes are 
small, uniform and characterized by low proliferation 
rates. Th  ese cells occur singly or in pairs, and in the 
resting zone the ECM takes more space than the cells. In 
the adjacent proliferative stage, the chondrocytes divide 
several times and the ﬂ  at cells arrange into longitudinal 
columns. Th   e expression repertoire now includes 
collagen VI [7] and matrilin 1 [8] in addition to the 
collagens II, IX and XI and aggrecan. During 
prehypertrophy, Indian hedgehog (Ihh) is expressed [9]. 
Further diﬀ   erentiation into hyper  trophic chondrocytes 
induces the production of collagen X. Hypertrophic 
chondrocytes also reduce, or even terminate, their 
production of collagens II, IX, and XI, and express 
MMP-13, alkaline phosphatase, vascular endothelial 
growth factor (VEGF), osteopontin, and the transcription 
factor Runx2 [10]. Collagen X, MMP-13, and alkaline 
phosphatase are well-established markers for the overt 
hypertrophic stage of late chondrocyte diﬀ  erentiation.
Regulation of chondrocyte diff  erentiation in 
growth cartilage
Chondrocyte diﬀ  erentiation in growth cartilage is subject 
to positive and negative control elements that interact 
within a signaling network to regulate the rate and 
progression of the process. EO is controlled by locally 
acting autocrine signals derived from chondrocytes 
themselves or by paracrine signals derived from cells of 
surrounding tissues (for example, the perichondrium or 
subchondral blood vessels). Th   e interaction of chondro-
cytes with their surrounding matrix via cell surface 
receptors is also thought to play a key role in the 
regulation of survival, proliferation and maturation of 
Figure 1. Organization of a 15-day-old murine tibia growth plate. Microphotograph of a Weigert’s hematoxylin/alcian blue/sirius red stained 
section. Diff  erent growth plate zones can be distinguished according to changes in morphology and arrangement of the cells.
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of chondrocyte diﬀ  erentiation as well as their cell surface 
receptors are proteins. Proteinases are thus not merely 
destructive eﬀ   ectors of ECM degradation but also 
intervene in regulatory networks, both by eliminating 
control elements (for example, endoplasmic reticulum 
protein 57 (ERp57) [11]) and by converting precursors 
into active agents (for example, transforming growth 
factor beta (TGFβ) [12]). In addition, proteinases 
modulate mediator activities by direct cleavage or by 
release from ECM stores (for example, VEGF [13]). Most 
signaling events culminate at the level of gene expression; 
thus transcription factors are also essential regulatory 
elements [10]. Several positive and negative feedback 
mechanisms exist, however, which complicate the 
signaling network.
Locally produced, secreted growth factors
Several locally produced factors – such as bone morpho-
genetic proteins (BMPs), ﬁ   broblast growth factors 
(FGFs), TGFβ, Wnts, Ihh, parathyroid hormone-related 
peptide and retinoids – are so far known to inﬂ  uence EO. 
Th   e actions of each of these growth factors during EO are 
brieﬂ  y summarized below.
BMP signaling initiates chondroprogenitor cell diﬀ  er-
en  tiation, but in later EO stages induces chondrocyte 
proliferation and inhibits hypertrophic diﬀ  erentiation via 
Smad transcription factors [14]. Proteins of the  FGF 
family, however, antagonize the BMPs. FGF-2 inhibits 
longitudinal bone growth by three mechanisms: decreased 
proliferation of growth plate chondrocytes, decreased 
cellular hypertrophy, and, at high concentrations, 
decreased cartilage matrix production. Th  ese  eﬀ  ects may 
explain the impaired growth seen in patients with 
achondroplasia and related skeletal dysplasias [15]. 
FGF-2 inhibits chondrocyte hypertrophy in synergy with 
TGFβ2 [16], while TGFβ alone inhibits chondrocyte 
proliferation, hypertrophy and mineralization [17]. In 
suspension cultures of chick sternum chondrocytes, 
TGFβ even initiates phenotypic changes of dediﬀ  eren-
tiation [18]. On the other hand, TGFβ1 has also been 
shown to increase alkaline phosphatase activity and to 
stimulate proliferation in rat costochondral cartilage cells 
through protein kinase C and protein kinase A signaling 
[19], suggesting a variability of TGFβ eﬀ  ects depending 
on the species, the diﬀ  erentiation status of the receiving 
cells and the TGFβ concentration.
Members of the Wnt family are involved in diﬀ  erent 
stages of EO. During mesenchymal condensation, Wnt 
signaling favors osteoblastic diﬀ  erentiation but prevents 
chondrogenic diﬀ   erentiation; whereas at later stages, 
canonical Wnt/β-catenin signaling is indispensable for 
chondrocyte maturation. Wnt/β-catenin signaling acts as 
a positive regulator of chondrocyte hypertrophy and 
subsequent ossiﬁ  cation [20]. Retroviral overexpression of 
Wnt9a (formerly known as Wnt14), one of the 19 ligands 
of the Wnt-signaling pathway, in chicken embryo limb 
buds results in a blockage of chondrogenic diﬀ  erentiation 
of the infected prechondrogenic region [21,22].
Ihh is expressed in the prehypertrophic chondrocytes 
of cartilage elements, where it regulates the rate of hyper-
trophic diﬀ  erentiation. In a feedback loop of paracrine 
control, perichondrial cells induced by the chondrocyte-
derived Ihh produce parathyroid hormone-related 
peptide, which delays progression of late diﬀ  erentiation 
at late proliferative stages [9]. Additionally, proteins of 
the hedgehog family can also accelerate hypertrophic 
chondrocyte diﬀ   erentiation without involvement of 
parathyroid hormone-related peptide in vitro and in vivo 
[23], suggesting a direct eﬀ   ect of hedgehog proteins, 
possibly depending on the maturation stage of the 
receiving cell.
Th   e vitamin A derivative retinoic acid positively regu-
lates hypertrophic chondrocyte diﬀ  erentiation  and 
matrix mineralization [24].
Hormones
In addition to locally produced growth factors, systemic 
hormones – such as growth hormone (GH), insulin-like 
growth factors (IGFs), thyroid hormone, androgen, 
estrogen and glucocorticoids – tightly regulate longi  tu-
dinal bone growth. Local and systemic agents control the 
rate and extent of chondrocyte proliferation and diﬀ  er-
entiation at several checkpoints. Th  is endocrine control 
enables longitudinal bone growth in healthy individuals 
and leads to increased growth rates and subsequent 
growth plate closure around puberty. GH and IGFs are 
potent stimulators of longitudinal bone growth. Both 
factors stimulate proliferation of resting zone chondro-
cytes and initiate chondrocyte hypertrophy [25]. Some 
eﬀ  ects of GH are likely to be mediated by IGF-I, with 
locally produced IGF-I seeming more important than 
systemic IGF-I [26].
Th  yroid hormone is also indispensable in EO. Hypo-
thyroidism slows down longitudinal bone growth, 
whereas hyperthyroidism accelerates the process. In vitro 
and in vivo studies have conﬁ  rmed that thyroid hormone 
regulates the transition between cell proliferation and 
terminal diﬀ  erentiation in the growth plate; speciﬁ  cally, 
the maturation of chondrocytes into hypertrophic cells. 
Administration of thyroid hormone dose-responsively 
increases synthesis of type X collagen mRNA and 
protein, alkaline phosphatase activity, and cellular 
hypertrophy, all markers of the terminally diﬀ  erentiated 
phenotype of the growth plate chondrocyte [27].
Sex steroids are essential during the pubertal growth 
spurt and epiphysial fusion. Androgen stimulates 
chondro  cyte proliferation and matrix production, and 
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during the pubertal growth spurt. Estrogen aﬀ  ects 
growth plate cartilage through systemic as well as direct 
eﬀ  ects. On the one hand, estrogen regulates the GH/IGF-I 
axis, leading to decreased longitudinal growth and 
closure of the growth plate [28]; but estrogen also 
interacts with its receptors α and β within the growth 
plate, mediating direct eﬀ  ects [29].
Th  e role of vitamin D signaling during bone develop-
ment is well known because vitamin D deﬁ  ciency leads to 
bone-softening diseases, such as rickets in children and 
osteomalacia in adults. Th  ese abnormalities result from 
decreased apoptosis of hypertrophic chondrocytes, 
widening of hypertrophic zones, and impaired bone 
mineralization. Some of the vitamin D eﬀ  ects are indirect 
through vitamin D actions on intestinal calcium and 
phosphate uptake. 24,25(OH)2 vitamin D3, however, 
directly reduces chondrocyte diﬀ   erentiation in resting 
zone chondrocytes and stimulates late diﬀ  erentiation, 
while 1,25(OH)2 vitamin D3 directly decreases prolifera-
tion and inhibits hypertrophic diﬀ   erentiation of pro-
liferative cells through binding to a membrane-associated 
rapid-response steroid receptor (ERp57) on growth plate 
chondrocytes [11,30].
Extracellular matrix molecules
An intact ﬁ  brillar periphery is a prerequisite for normal 
cellular architecture of the growth plate, with collagen IX 
being particularly important for proliferation and 
maturation of chondrocytes. Newborn mice lacking 
collagen IX develop abnormal areas with strongly 
reduced cell numbers within the epiphysis of long bones. 
In addition, a disturbed columnar arrangement of chon-
dro    cytes was detectable, resulting in shorter and broader 
long bones especially in newborn collagen IX-deﬁ  cient 
mice [31]. Th   e importance of cell-matrix interactions also 
was demonstrated in mice deﬁ  cient in receptor proteins 
on chondrocytes that interact with ECM molecules. 
Integrins α1β1, α2β1, and α10β1 are the major collagen 
receptors in cartilage. Th   eir role in the spatial 
arrangement of growth plate chondrocytes and in 
outside-in-signaling has been intensively studied. 
Integrins, and their downstream signals integrin-linked 
kinase and the Rho GTPase Rac1, seem to act in a 
common pathway regulating cartilage development and 
disturbances in outside-in-signaling from the ECM to the 
cytoskeleton contribute to severe skeletal phenotypes 
[32-34].
Integrins are not the only ECM receptors in cartilage. 
Th   e discoidin domain receptors (DDRs) are members of 
a subfamily of tyrosine kinase receptors that are activated 
by a number of diﬀ  erent collagens, amongst others by 
collagens II and X. DDRs regulate cell proliferation, 
adhesion and motility, and control remodeling of the 
ECM by inﬂ  uencing the expression and activity of MMPs; 
for example, MMP-13 [35]. Mice lacking DDR2 exhibit 
dwarﬁ  sm due to decreased proliferation of growth plate 
chondrocytes [36].
Proteases
MMPs are members of a family of zinc-dependent 
proteolytic enzymes. Several MMPs are expressed in 
bone and cartilage at high levels and are essential for 
normal EO. MMPs are directly involved in the degra-
dation of proteins such as collagens and proteoglycans 
necessary for remodeling of the cartilaginous template 
during EO. Of further interest are the ECM degradation 
products, called matrikines, which are involved in the 
induction of higher concentrations or additional cata-
bolic enzymes, amplifying the ECM remodel  ing. In 
addition to ECM degradation, however, several proteases 
are involved in the recruitment of cells into the growth 
plate through activation of recruitment factors (for 
example, VEGF) or inﬂ   uencing their bioavailability 
within the matrix [13].
Bone phenotypes are detectable in several mouse 
strains with MMP deﬁ  ciencies. Although hypertrophic 
chondrocytes of MMP-9-deﬁ   cient animals develop 
normally, apoptosis, vascularization, and ossiﬁ  cation are 
delayed, resulting in progressive lengthening of the 
growth plate [37].  Wu and colleagues observed that 
MMP-13 activity is required for chondrocyte diﬀ  eren-
tiation associated with matrix mineralization [38]. 
Studies on mice with compound inactivation of the 
MMP-9 and MMP-13 genes reveal that both proteases 
act in a synergistic manner. Th   e double-null mice display 
severely impaired endochondral bone formation, charac-
ter  ized by diminished ECM remodeling, prolonged 
chondrocyte survival, delayed vascular recruitment and 
defective trabecular bone formation, resulting in 
drastically shortened bones [39]. MT1-MMP (MMP-14) 
deﬁ  ciency causes a delay in the formation of the ﬁ  rst and 
second ossiﬁ  cation centers, a disorganized proliferation 
zone with reduced proliferation of chondrocytes, and an 
expanded zone of hypertrophic chondrocytes [40]. In 
addition the cysteine proteinases, especially the cathep-
sins, have also been implicated in several proteolytic 
scenarios during development, growth, remodeling, and 
aging. Th   roughout endochondral ossiﬁ  cation, cathepsins 
B, H, K, L, and S were detected immunohistochemically 
in growth plates of rats and humans [41] and are thought 
to be involved in the proteolysis of several ECM compo-
nents. We could show that cysteine proteinases mediate 
the shedding of 1,25(OH)2 vitamin D3 membrane-
associated rapid-response steroid receptor (endoplasmic 
reticulum protein 57), trigger chondrocyte size expansion 
and trigger expression of collagen X, alkaline phospha-
tase, and MMP-13 as markers for overt hypertrophy [11].
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Gene expression during distinct chondrocyte maturation 
phases within the epiphysial cartilage or growth plates is 
controlled by transcription factors translating the 
environmental signals into regulated gene expression. 
Th  e two main transcriptional regulators of chondro-
genesis and hypertrophic diﬀ   erentiation – Sox9 and 
Runx2 – should be addressed.
Sox9 was characterized as the master gene of chondro-
genesis that regulates proliferation and diﬀ  erentiation of 
nonhypertr    ophic chondrocytes. Along with Sox5 and 
Sox6, Sox9 regulates the expression of aggrecan, and the 
α1 chains of collagen II and collagen XI [42]. In addition, 
Sox9 acts as a negative regulator of chondrocyte 
hypertrophy, cartilage vascularization, and bone marrow 
formation [43].
Runx2 and its relative Runx3 are central positive 
regulators of the transition from proliferating to hyper-
trophic chondrocytes. Runx2/3 double-deﬁ  cient  mice 
were shown to lack hypertrophic chondrocytes anywhere 
in the skeleton [44]. In addition, Runx2-deﬁ  cient mice 
lack upregulation of VEGF in hypertrophic chondrocytes 
and thus cartilage angiogenesis, suggesting that VEGF 
expression during bone development is controlled by the 
transcription factor Runx2 [45].
Another important transcription factor in bone 
develop  ment, detected recently, is CCAAT/enhancer-
binding protein beta (C/EBPβ). C/EBPβ deﬁ  ciency  in 
mice was shown to cause dwarﬁ   sm with elongated 
proliferative zones and delayed chondrocyte hypertrophy 
in growth cartilage [46]. Since growth arrest and DNA 
damage (GADD)45β–/– animals [47] display similar 
phenotypes to the C/EBPβ knockout mice [46], the 
molecular interplay of GADD45β and C/ERBβ was 
analyzed in further detail. Various experiments indicate 
that GADD45β enhances C/ERBβ transactivation of the 
collagen 10a1 promoter and therefore is an upstream 
modulator of C/EBPβ [48].
Chondrocyte diff  erentiation processes in articular 
cartilage
Articular cartilage is formed for life. Articular chondro-
cytes therefore display only moderate metabolic activity 
under normal conditions, primarily to maintain their 
surrounding ECM comprising collagens (collagens II, VI, 
IX and XI), proteoglycans (aggrecan, decorin, biglycan 
and ﬁ   bromodulin) and further noncollagenous matrix 
proteins. Under nondiseased conditions, the cells remain 
in a resting state and refrain from proliferation or ter  mi-
nal diﬀ   erentiation. In a diseased state, however, some 
articular chondrocytes lose their diﬀ  erentiated pheno-
type; they enter an EO-like cascade of proliferation [49] 
and hypertrophic diﬀ  erentiation, accompanied by marker 
expression for the overt hypertrophic diﬀ  eren  tiation 
stage, such as alkaline phosphatase [50], collagen X [51], 
and MMP-13 [52], with subsequent apoptotic death [53] 
and mineralization of the diseased cartilage [54] (Figure 
2).
OA is considered a multifactorial disease; however, the 
scenario that OA is, at least in part, based on illegitimate 
hypertrophic diﬀ   erentiation should be taken into 
account. Diﬀ   erentiation of chondrocytes leads to an 
enhanced metabolic activity of articular chondrocytes, a 
change in the expression of ECM molecules, and an 
altered pattern of proteases. Altogether, this diﬀ  eren-
tiation triggers a disturbed cartilage homeostasis favoring 
degenerative changes. Several signaling factors involved 
in chondrocyte proliferation and diﬀ  erentiation during 
endochondral ossiﬁ   cation were also shown to play a 
regulative role in OA cartilage, but not under non-
diseased conditions. In all cases in which this signaling 
initiates the modulation of ECM or the expression or 
activation of proteases (for example, MMP-13 or 
aggrecanases), diﬀ   erentiation changes should be con-
sidered a potential driver of OA. A number of examples 
illustrating the analogy of signaling events in bone 
development by EO and cartilage degeneration in OA are 
given below. Th  e reader should, however, keep in mind 
that most of the factors reviewed here were analyzed in 
spontaneous, transgenic or surgically induced mouse 
models of OA but not in large animals, which 
occasionally better reﬂ  ect human OA pathophysiology.
Growth factor signaling in osteoarthritis
Chondrocyte diﬀ   erentiation and matrix remodeling in 
osteoarthritic cartilage is regulated by BMPs, FGF-2, 
TGF-β, Wnts, hedgehogs and retinoids – all of which are 
also involved in the regulation of EO.
Although BMP-2 has potent anabolic actions, BMP 
activity in chondrosarcoma cells and in murine cartilage 
was shown to induce OA-like changes by stimulation of 
MMP-13 [55], directly favoring cartilage loss. FGF-2, 
however, displays beneﬁ  cial eﬀ  ects on articular cartilage 
homeostasis. Chia and colleagues observed that FGF-2-
deﬁ  cient mice had increased OA development with age 
as compared with wild-type mice. Th  is is due to an 
increased expression of ADAMTS-5, the key murine 
aggrecanase [56]. Th  e contrary role of BMP and FGF 
signaling pathways in OA was also described recently in 
respect of extracellular heparan sulfatases Sulf-1 and 
Sulf-2, which are found overexpressed in OA cartilage. 
Sulfs simul  taneously enhance BMP signaling via Smad1/5 
phos  phorylation but inhibit FGF signaling via ERK1/2 
phosphory  lation, and thereby maintain cartilage homeo-
stasis and favor cartilage repair [57].
Lack of TGFβ signaling results in OA-like changes with 
terminal diﬀ   erentiation of chondrocytes. As shown in 
genetically modiﬁ  ed mice, TGFβ mediates this eﬀ  ect by 
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quent activation of the Smad2/3 intracellular signaling 
route [17,58]. Notably, TGFβ supplementation can 
enhance cartilage repair and therefore was thought to 
serve as a potential therapeutic tool. Conversely, supple-
men  tation with TGFβ provides problems in non-
cartilaginous tissues of the joint and results in ﬁ  brosis 
and osteophyte formation in a murine model of OA [59]. 
Moreover, Van der Kraan and colleagues recently 
suggested a dual role for TGFβ in articular mouse 
cartilage because not only signaling via ALK5 (Smad2/3) 
but also via ALK1 (Smad1/5/8) can be initiated by TGFβ. 
Importantly, only signaling via ALK1, but not via ALK5, 
stimulates MMP-13 expression and thereby collagen 
degradation [60].
Recent genetic data of Caucasian test persons linked a 
polymorphism in the FrzB gene, encoding for a Wnt 
binding protein, to the development of OA, suggesting 
that abnormal Wnt signaling also contributes to OA [61]. 
Blom and colleagues found that β-catenin, along with a 
panel of other Wnt/Fz-related genes, was upregulated in 
cartilage and synovium during experimental OA in mice. 
Th  e authors identiﬁ   ed WISP-1 (capable of inducing 
cartilage-degrading enzymes such as MMPs, ADAMTS-4 
and ADAMTS-5), independently of the catabolic cyto-
kine IL-1, as a crucial Wnt signaling mediator [62].
Moreover recent studies using a transgenic OA mouse 
model with conditional activation of the β-catenin gene 
in articular chondrocytes showed that upregulation of β-
catenin signaling is most probably responsible for the 
conversion of normal articular chondrocytes into 
arthritic, OA-like cells. Chondrocyte maturational genes 
were activated along with the induction of matrix 
degradation [63,64]. Hedgehog signaling was also des-
cribed to play a role in OA. Lin and colleagues demon-
strated an increased expression of hedgehog targets in 
human OA samples and mouse articular cartilage after 
surgical OA induction. Ampliﬁ  ed hedge  hog target gene 
Figure 2. Knee cartilage showing increased hypertrophy and mineralization. Knee cartilage with higher Mankin scores shows increased 
hypertrophy (increase in collagen X staining; fast blue) and mineralization (arrowheads). Histologic assessment of the knee was performed on 
cartilage plugs from the medial femoral condyle, and a modifi  ed Mankin scoring system was used to assess the severity of changes in osteoarthritis 
(OA) articular cartilage. The Mankin grades (range 0 to 14 points) for mild (1), moderate (2), and severe (3) OA were 2 to 5, 6 to 9, and 10 to 14 points, 
respectively. To assess hypertrophic diff  erentiation, collagen X staining was performed on paraffi     n sections after hyaluronidase (Sigma, Taufkirchen, 
Germany) digestion with collagen X antibody (ab58632; Abcam, Cambridge, UK) using the Vectastain ABC Elite Kit (Vector Laboratories, Peterborough, 
UK) and fast blue as a chromogen. To assess mineralization, the articular cartilage was analyzed using digital contact radiography (DCR), performed 
using a digital mammography imaging technique (Hologic, Waltham, MA, USA) operating at 25 kV in manual mode, usually at 3.8 mA, and with a fi  lm 
focus distance of 8 cm. See [54]. Photographs kindly provided by Martin Fuerst, University Medical Center Hamburg-Eppendorf.
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hedgehogs were described to stimulate the expression of 
the aggrecanase ADAMTS-5 via the transcription factor 
Runx2 [65].
Last, but not least, the retinoids display multiple eﬀ  ects 
relevant to the OA disease process. Davies and colleagues 
showed that components of the retinoid signaling 
pathways are upregulated during OA in humans and that 
all-trans-retinoic acid treatment of human explant 
cartilage samples led to signiﬁ  cant increase of MMP-13 
and aggrecanases, enzymes involved in two of the key 
proteolytic processes implicated in OA [66]. Taken 
together, many locally acting growth factors playing a 
crucial role in the regulation of chondrocyte proliferation 
and diﬀ  erentiation during EO also are involved in OA 
pathogenesis and disease progression, mainly by stimu  la-
tion or activation of degradative enzymes (for example, 
MMP-13 or aggrecanases).
Role of hormones in osteoarthritis
A number of diﬀ   erent studies have attempted to link 
changes in hormonal status to the pathogenesis or 
progression of OA, but in the majority of cases incon-
sistent results were obtained. Th   e prevalence of knee OA, 
for example, is increased among woman after the age of 50 
years, and this phenomenon has been ascribed to estrogen 
insuﬃ     ciency. No clear association has yet been found, 
however, between hormone deﬁ   ciency and OA of the 
hand, hip and knee [67]. Reports about estrogen 
replacement therapies and their outcome on OA incidence 
also show inconsistent results [68]. In addition to estrogen, 
the vitamin D status is unrelated to the risk of joint space 
or cartilage loss in knee OA [69]. Moreover, no association 
was found between vitamin D receptor polymorphisms 
and OA susceptibility in a large meta-analysis [70].
With respect to the GH/IGF-I axis, however, it was 
shown in a rat model of OA that chronic GH deﬁ  ciency 
causes an increased severity of articular cartilage lesions 
of OA, although the IGF-I expression is increased [71]. 
Anabolic IGF-I signaling is antagonized by increased 
occurrence of IGF-binding proteins, which then nega-
tively regulate IGF-I signaling in chondrocytes during 
OA [72]. In contrast, patients with GH deﬁ  ciency had 
signiﬁ  cantly less OA than the normal patients of a control 
population, suggesting GH to be a beneﬁ  cial factor in the 
development of OA [73].
Role of extracellular matrix molecules in osteoarthritis
Cell-matrix interactions are essential regulators, both in 
EO and OA. One such example is deﬁ   ciency in the 
collagen IX α1 chain, a periﬁ   brillar component of 
cartilage ﬁ  brils, containing collagens II and XI. Knockout 
animals were not only shown to have a growth plate 
phenotype but also to develop a severe degenerative joint 
disease resembling human OA [74,75]. Histological 
analysis reveals OA-like changes in an age-dependent 
manner in the knee and temporomandibular joints 
starting at the age of 3 months. Later, at the age of 
6 months, enhanced proteoglycan and collagen degrada-
tion due to higher expression of MMP-13 was observed. 
Th   e FACIT collagen IX is directly and indirectly involved 
in the mutual interaction of the extraﬁ  brillar  matrix 
components with cartilage ﬁ   brils [76]. Th  e disturbed 
tissue integrity possibly triggers a higher susceptibility of 
collagen IX α1 knockout animals to cartilage degradation.
Furthermore, as in EO, matrix receptors binding to the 
structural components of the ECM have an impact on 
chondrocyte behavior in articular cartilage. One such 
example is the deﬁ  ciency of the α1 subunit of integrins, 
which in mice was detected to be associated with an 
accelerated, aging-dependent development of OA [77]. 
Mice with a conditional deletion of the β1-integrin gene 
in early limb development using a mitochondrial peroxi-
redoxin Prx1-cre transgene showed multiple abnor-
malities of knee-joint articular cartilage, accompanied by 
accelerated terminal diﬀ  erentiation.  Th  e  cartilage 
homeo  stasis in these mice, however, was comparable 
with wild-type animals, suggesting a minor importance 
of signaling events mediated through integrins in 
cartilage destruction [78].
Other examples aﬀ  ecting chondrocyte behavior, how-
ever, are the DDR receptors. Xu and colleagues detected 
that increased expression of the collagen receptor DDR-2 
in articular cartilage represents a key event in the 
pathogenesis of OA [79]. Th   e authors not only describe 
increased immunostaining for DDR-2 but also for 
MMP-13 and MMP-derived type II collagen fragments in 
cartilage from patients with OA and from mice with 
surgically induced OA, and they linked the enhanced 
MMP-13 expression by mutation analysis directly to 
enhanced DDR-2 signaling. Based on these observations, 
they hypothesized that exposure of the type II collagen 
network to chondrocytes results in enhanced contact of 
the cells with type II collagen ﬁ  brils. DDR-2 is activated 
as a consequence of the interaction of type II collagen 
with chondrocytes, resulting in the increased expression 
of the receptor itself as well as MMP-13. Increased 
expression of DDR-2 may thus be a common event in the 
pathogenesis of OA in general [79].
Role of proteases in osteoarthritis
Proteolytic degradation of articular cartilage involving 
the key players of the MMP family, the a disintegrin and 
metalloprotease (ADAM) family and the ADAMTS 
protease family is a central event during OA. Th  e 
structural integrity of the ECM is damaged by these 
enzyme activities, and cell-matrix interactions inﬂ  uencing 
chondrocyte activities are destroyed.
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human OA, only the lack of ADAMTS-5  prevented 
cartilage degradation in a mouse model of surgically 
induced OA [80]. Remarkably, the heparan sulfate 
proteo  glycan syndecan-4 regulates ADAMTS-5 activa-
tion and cartilage breakdown in murine OA through 
direct interaction with the protease and through 
regulating mitogen-activated protein kinase-dependent 
synthesis of MMP-3 [81]. To investigate the role of 
MMP-13 in cartilage degradation and chondrocyte 
diﬀ  er  entiation during OA, Little and colleagues surgically 
induced OA in the knees of MMP-13-deﬁ  cient and wild-
type mice. Th   ese authors observed that MMP-13 
deﬁ  ciency can inhibit cartilage erosion but not chondro-
cyte hypertrophy or osteophyte generation during OA, 
suggesting that chondrocyte hypertrophy is accompanied 
by, but not directly regulated by, MMP-13 [82]. Tchetina 
and colleagues investigated the interrelationship between 
the extent of collagen cleavage by collagenases and the 
expression of diﬀ   erentiation-related genes [83]. Th  ese 
Table 1. Diff  erent signaling factors involved in both chondrocyte diff  erentiation processes during endochondral 
ossifi  cation and in osteoarthritis
Signaling factor  Eff  ects on growth plate chondrocytes  Role in OA
Bone morphogenic proteins  Induce proliferation  Stimulation of MMP-13
 Inhibit  hypertrophy 
Fibroblast growth factors  Decrease proliferation  Stimulation of ADAMTS-5
 Decrease  hypertrophy 
  Decrease matrix production 
TGFβ Variable  eff  ects depending on species and concentration   Stimulation of MMP-13 
Wnt/β-catenin  Positive regulator of hypertrophy and ossifi  cation  Activation of maturational genes
    Induction of matrix degradation
    Induction of MMPs and aggrecanases mediated by WISP-1
Indian hedgehog  Stimulates proliferation  Induction of ADAMTS-5 via Runx2
  Inhibits hypertrophy via parathyroid hormone-related peptide 
  Directly induces hypertrophy in vitro 
Retinoic acid  Positive regulator of hypertrophy and matrix mineralization  Induction of MMP-13 and aggrecanases
Growth hormone/IGF-I  Stimulate proliferation  Growth hormone is a benefi  cial factor in OA
  Initiate hypertrophy  IGF-I signaling is antagonized by IGF-binding proteins
Collagen IX  Stimulates chondrocyte proliferation  Essential for tissue integrity, loss of collagen IX induces OA
  Essential for columnar organization of growth plate chondrocytes 
β1 integrins  Mediate adhesion to surrounding matrix and motility  Essential for normal knee joint development 
  Essential for proliferation  Minor infl  uence on cartilage homeostasis
Discoidin domain receptors  Regulate cell proliferation, adhesion and motility  Induction of MMP-13 and MMP-derived type II collagen 
   fragments
  Control matrix remodeling 
MMPs/ADAMTSs  Essential for matrix remodeling  Key factors in matrix degradation during OA
  Infl  uence bioavailability of VEGF   Matrix degradation is accompanied by terminal 
   chondrocyte  diff  erentiation, positive feedback 
   mechanism?
Sox 9  Regulate proliferation and hypertrophic diff  erentiation  Involved in MMP-13 expression
Runx2/3  Positive regulation of chondrocyte hypertrophy  Induction of chondrocyte hypertrophy 
  Infl  uence on angiogenesis by upregulation of VEGF  Induction of MMP-13 expression
CCAAT/enhancer binding  Inhibition of proliferation   Mediates cartilage destruction
protein beta
  Stimulation of hypertrophy 
  Activation of collagen X expression 
Note that cartilage degradation in osteoarthritis (OA) is mediated by matrix metalloproteinase (MMP)-13 and aggrecanases (a disintegrin and metalloprotease with 
trombospondine motifs (ADAMTS)-4 and ADAMTS-5) expressed by hypertrophic chondrocytes. See relevant references in the text. IGF, insulin-like growth factor; 
TGFβ, transforming growth factor beta; VEGF, vascular endothelial growth factor.
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Page 8 of 11authors detected that early focal cartilage degradation by 
MMP-1, MMP-14 and ADAMTS-5 was accompanied by 
the expression of terminal diﬀ  erentiation-related genes 
COL10A1, MMP-13, MMP-9, Ihh and caspase 3, 
suggesting that chondrocyte diﬀ   erentiation may be 
closely related to the very early development of cartilage 
degeneration. Taken together these results indicate that 
matrix remodeling processes show similar characteristics 
in EO and OA.
Role of transcription factors in osteoarthritis
Orfanidou and colleagues recently investigated the 
involvement of the most fundamental transcription 
factors in EO – Runx2 and Sox9 – in the regulation of 
osteoarthritic chondrocytes. Th  e authors demonstrated 
convincing associations among Runx2, Sox9 and FGF-23 
in relation to MMP-13 expression in osteoarthritic 
chondrocytes, contributing to the cartilage degeneration 
process [84]. Kamekura and colleagues surgically induced 
OA in Runx2+/–-deﬁ  cient mice and wild-type mice. Th  e 
heterozygous Runx2-deﬁ  cient mice exhibited decreased 
cartilage destruction and osteophyte formation, along 
with reduced type X collagen and MMP-13 expression, as 
compared with wild-type mice – suggesting a contri-
bution of the transcription factor Runx2 to the patho-
genesis of OA through chondrocyte hypertrophy and 
matrix breakdown after the induction of joint instability 
[85]. Taken together, these two major transcriptional 
regulators of chondrogenesis and hypertrophic diﬀ  eren-
tiation (Sox9 and Runx2) play a role not only in bone 
development by EO but also in cartilage degradation in 
OA.
Th   e transcription factor C/EBPβ was shown to directly 
transactivate p57Kip2 to promote the transition from 
proliferation to hypertrophic diﬀ  erentiation of chondro-
cytes and to inﬂ  uence the collagen type X expression 
during bone development [46,48]. Th  is transcription 
factor mediates cartilage destruction during OA progres-
sion, since C/EBPβ+/– mice were protected against 
cartilage degradation in knee joints in an OA model [46]. 
Whether GADD45β is an upstream modulator of 
C/EBPβ in this instability-induced OA in mice, as was 
shown in chondrocyte terminal diﬀ  erentiation, needs to 
be shown in future experiments.
Conclusions
A number of signaling factors involved in chondrocyte 
proliferation and diﬀ   erentiation during EO were also 
shown to play a regulative role in articular cartilage 
during OA, pointing towards analogous signaling events 
that are critical for both scenarios (Table 1). All events 
leading to a structurally altered ECM in articular 
cartilage – for example, reduction in cartilage collagen 
production or induction of degradative enzymes – have 
to be taken into account as the driving force in the 
pathogenesis or progression of OA. Future work is 
necessary to investigate both of these processes in further 
detail in order to take advantage of the understanding of 
developmental aspects for pathogenetic mechanisms of 
degenerative joint disorders, and hence the successful 
development of future therapeutic strategies.
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